Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction

Provided By Globe Newswire

Last update: May 23, 2022

Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial

Next development steps for XOWNA^® to be announced by year-end 2022 following regulatory and business review